Publications by authors named "Ana Pertejo"
Introduction: Systemic therapy of patients with metastatic renal cell carcinoma (mRCC) has improved in the past years, with the advent of new immunotherapy-based combinations as a standard treatment option for first-line therapy. Nevertheless, particularly in good-risk patients by IMDC criteria, tyrosine-kinase inhibitors (TKI) may remain as an option for some patients. We reviewed our experience with TKI as first-line therapy for mRCC patients, trying to identify subgroups of patients that may still benefit from this strategy.
View Article and Find Full Text PDFPurpose: To explore the tumor proteome of patients diagnosed with localized clear cell renal cancer (ccRCC) and treated with surgery.
Material And Methods: A total of 165 FFPE tumor samples from patients diagnosed with ccRCC were analyzed using DIA-proteomics. Proteomics ccRCC subtypes were defined using a consensus cluster algorithm (CCA) and characterized by a functional approach using probabilistic graphical models and survival analyses.
Article Synopsis
- Docetaxel is standardly administered at 75 mg/m every 3 weeks for metastatic prostate cancer, but a lower dose of 50 mg/m every 2 weeks may be better for frail patients.
- A retrospective study of 200 patients revealed that those on the 2-weekly schedule were older and had more health issues, but it didn't significantly impact survival when accounting for other factors.
- While the 2-week schedule had more treatment delays and suspensions, it led to fewer severe toxicities, suggesting it could be a viable option for older, frailer patients.
Trastuzumab therapy has dramatically changed breast cancer prognosis. Consensus documents recommend a close monitoring during therapy, not always feasible, especially in metastatic breast cancer. The purpose of this study is to describe trastuzumab cardiotoxicity in metastatic breast cancer patients to understand how to improve cardiovascular monitoring.
View Article and Find Full Text PDFBackground: Approximately 15% of patients infected by SARS-CoV-2 develop a distress syndrome secondary to a host hyperinflammatory response induced by a cytokine storm. Myelosuppression is associated with a higher risk of infections and mortality. There are data to support methods of management for neutropenia and COVID-19.
View Article and Find Full Text PDF